Inclusion Criteria:
  1. Histologically confirmed aggressive NHL
  2. Mantle cell lymphoma
  3. salvage chemotherapy sensitive relapse/refractory NHL or high risk NHL with remission in induction chemotherapy
  4. Performance status: Eastern Cooperative Oncology Group (ECOG) 0-2.
  5. Age; 18-65
  6. Adequate renal function: serum creatinine â‰¤ 1.5mg/dL
  7. Adequate liver functions: Transaminase (AST/ALT) < 3 X upper normal value & Bilirubin
     < 2 X upper normal value
Exclusion Criteria:
  1. low grade NHL
  2. Any other malignancies within the past 5 years except curatively treated non-melanoma skin cancer or in situ carcinoma of cervix uteri
  3. Other serious illness or medical conditions
       -  Unstable cardiac disease despite treatment, myocardial infarction within 6 months prior to study entry
       -  History of significant neurological or psychiatric disorders
       -  Active uncontrolled infection (viral, bacterial or fungal infection)
  4. Pregnant or lactating women, women of childbearing potential not employing adequate contraception
  5. HIV (+)
  6. Patients who have hepatitis B virus (HBV) (+) are eligible. However, primary prophylaxis using antiviral agents (i.e. lamivudine) is recommended for HBV carrier to prevent HBV reactivation during whole treatment period -